Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00492895

Enrollment

Registered

2007-06-27

Start date

2007-06-30

Completion date

2011-03-31

Last updated

2013-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Cancer

Brief summary

Photosensitivity of the skin to UVA and UVB will be determined

Detailed description

Photosensitivity of the skin to UVA and UVB in renal transplant recipients with and without azathioprine will be determined. Azathioprine will be discontinued and photosensitivity determined after a wash-out period of three months * Trial with medicinal product

Interventions

DRUGDiscontinuation of Azathioprin

Discontinuation of Azathioprin

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Renal transplant recipients under azathioprin

Exclusion criteria

* Treatment with Prograf (Tacrolimus)

Design outcomes

Primary

Measure	Time frame
Photosensitivity of the skin to UVA and UVB	2 years

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026